| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tozorakimab | MEDI-3506 | Phase 3 Clinical | Medimmune | Asthma; Bronchitis, Chronic; Dermatitis, Atopic; Diabetic Nephropathies; Pneumonia, Viral; Pulmonary Disease, Chronic Obstructive | Details |
| Itepekimab | REGN-3500; SAR-440340 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc, Sanofi | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| Etokimab | ANB-020 | Phase 2 Clinical | Anaptysbio Inc | Asthma; Dermatitis, Atopic; Hypersensitivity; Peanut Hypersensitivity; Pulmonary Eosinophilia; Sinusitis | Details |
| MT-2990 | MT-2990 | Phase 2 Clinical | Mitsubishi Tanabe Pharma Corp | Endometriosis; Pain; Rhinitis, Allergic, Seasonal; Vasculitis | Details |
| GSK-3862995 | GSK-3862995B; GSK3862995; GSK-3862995; GSK3862995B | Phase 2 Clinical | Glaxosmithkline Plc | Bronchiectasis; Pulmonary Disease, Chronic Obstructive | Details |
| Ompekimig | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
| SSGJ-621 | SSGJ-621; 621 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| CAN-10 | CAN-10 | Phase 1 Clinical | Lund University Foundation | Myocarditis; Plaque psoriasis; Scleroderma, Systemic | Details |
| QX-007N | QX-007N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
